Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab versus aflibercept for systemic VEGF dynamics in neovascular age-related macular degeneration
2014-001182-27Phase 4Terminated
- Sponsor
- Novartis
- Start
- Jun 2014
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial in exudative macular degeneration comparing Monthly ranibizumab with Monthly aflibercept (2 arms). Primary endpoint: Systemic VEGF-A protein levels from baseline to week 12. Started Jun 2014; status: terminated.
02
Drugs
ranibizumabaflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2014-001182-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001182-27.